Family Heart Foundation® launches new initiative to increase understanding and screening for high lipoprotein(a), the most common genetic risk factor for premature cardiovascular disease
Business Announcement
Updates every hour. Last Updated: 29-Dec-2025 08:11 ET (29-Dec-2025 13:11 GMT/UTC)
The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RE™ initiative to engage key U.S. healthcare stakeholders in advancing awareness, screening and diagnosis of high lipoprotein(a) – also known as Lp(a). It is estimated that approximately 20% of the U.S. population has a genetic mutation for high Lp(a), yet only 1% in the general population, and 2% with established atherosclerotic cardiovascular disease (ASCVD), have been tested for Lp(a).
Eli Lilly and Company is the initial sponsor of the Family Heart Foundation’s two-year Lp(a) AW(a)RE initiative. Designed for primary care clinicians, healthcare insurance providers and policy makers, Lp(a) AW(a)RE includes educational symposia presented at professional conferences across the U.S. In addition, many of these events will also offer free Lp(a) screenings and educational materials.
Education experts at the University of South Australia say that to address teacher shortages, Australia must develop stronger government policies focused on the retention and career development of early career teachers, particularly those in casual and short-term contract roles.
The Society for Neuroscience (SfN) will present eight individuals and groups with this year’s Science Education and Outreach Awards, comprised of the Award for Education in Neuroscience, the Science Educator Award, the Next Generation Awards, and the Chapter of the Year Awards. The awards will be presented during SfN’s annual meeting.